RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Second Xiangya Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06975384, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed diagnosis of NSCLC;

    Inclusion criterion 2

    Histologically confirmed diagnosis of SCLC;

    Inclusion criterion 10

    Pathologically diagnosed as NSCLC;

    Inclusion criterion 18

    Pathologically diagnosed as NSCLC;

    Inclusion criterion 26

    Pathologically stage confirmed as early stage of IA-IIIA;

    Inclusion criterion 27

    Histologically confirmed diagnosis of NSCLC;

    Inclusion criterion 33

  3. Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;

    Inclusion criterion 3

    Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;

    Inclusion criterion 11

    Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;

    Inclusion criterion 19

    Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;

    Inclusion criterion 34

  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;

    Inclusion criterion 4

    ECOG PS of 0-1;

    Inclusion criterion 12

    ECOG PS of 0-1;

    Inclusion criterion 35

  5. Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) fusion and/or ROS proto-oncogene 1 (ROS1) fusion-positive;

    Exclusion criterion 1

    EGFR-sensitizing mutation and/or ALK fusion and/or ROS1 fusion-positive;

    Exclusion criterion 14

  6. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1);

    Inclusion criterion 6

    Presence of at least one measurable lesion according to the RECIST v1.1 ;

    Inclusion criterion 14

    At least one measurable lesion can be evaluated according to the RECIST v1.1;

    Inclusion criterion 20

    Presence of at least one measurable lesion according to the RECIST v1.1;

    Inclusion criterion 37

  7. Presence of other malignant tumors or malignant diseases within 3 years;

    Exclusion criterion 2

    Presence of other malignant tumors or malignant diseases within 3 years;

    Exclusion criterion 8

    Presence of other malignant tumors or malignant diseases within 3 years;

    Exclusion criterion 15

    Presence of other malignant tumors or malignant diseases within 3 years;

    Exclusion criterion 21

    Presence of other malignant tumors or malignant diseases within 3 years;

    Exclusion criterion 26

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06975384, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Cohort 1:

Inclusion Criteria:

  • Age ≥ 18 years old;
  • Histologically confirmed diagnosis of NSCLC;
  • Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
  • Treatment naïve;
  • Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1);
  • Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
  • Informed consent to participate in the study;

Exclusion Criteria:

  • Epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) fusion and/or ROS proto-oncogene 1 (ROS1) fusion-positive;
  • Presence of other malignant tumors or malignant diseases within 3 years;
  • Concurrent acute or chronic psychiatric disorders;
  • Patients receiving sleep medication;
  • Prior participation in other clinical drug trials;
  • Symptomatic brain metastasis;
  • Inability to complete scale assessments.

Cohort 2:

Inclusion Criteria:

  • Age ≥ 18 years old;
  • Histologically confirmed diagnosis of SCLC;
  • Unresectable locally advanced, metastatic, or recurrent stage Ⅲ-Ⅳ based on AJCC TNM staging 8th edition;
  • ECOG PS of 0-1;
  • Treatment naïve;
  • Presence of at least one measurable lesion according to the RECIST v1.1 ;
  • Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy;
  • Informed consent to participate in the study;

Exclusion Criteria:

  • Presence of other malignant tumors or malignant diseases within 3 years;
  • Concurrent acute or chronic psychiatric disorders;
  • Patients receiving sleep medication;
  • Prior participation in other clinical drug trials;
  • Symptomatic brain metastasis;
  • Inability to complete scale assessments.

Cohort 3:

Inclusion Criteria:

  • Age ≥18 years old;
  • Pathologically diagnosed as NSCLC;
  • Resectable clinical stage IB-IIIB based on AJCC TNM staging 8th edition;
  • At least one measurable lesion can be evaluated according to the RECIST v1.1;
  • Treatment naïve;
  • Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy as neoadjuvant therapy;
  • Cardiopulmonary function can withstand surgery;
  • Informed consent to participate in the study.

Exclusion Criteria:

  • EGFR-sensitizing mutation and/or ALK fusion and/or ROS1 fusion-positive;
  • Presence of other malignant tumors or malignant diseases within 3 years;
  • Concurrent acute or chronic psychiatric disorders;
  • Patients receiving sleep medication;
  • Prior participation in other clinical drug trials;
  • Symptomatic brain metastasis;
  • Inability to complete scale assessments.

Cohort 4:

Inclusion Criteria:

  • Age ≥ 18 years old;
  • Pathologically diagnosed as NSCLC;
  • Pathologically stage confirmed as early stage of IA-IIIA;
  • Available for tumor tissue samples;
  • Treatment naïve;
  • Receiving radical surgery;
  • Informed consent to participate in the study;

Exclusion Criteria:

  • Presence of other malignant tumors or malignant diseases within 3 years;
  • Concurrent acute or chronic psychiatric disorders;
  • Patients receiving sleep medication;
  • Prior participation in other clinical drug trials;
  • Inability to complete scale assessments.

Cohort 5:

Inclusion Criteria:

  • Age ≥ 18 years old;
  • Histologically confirmed diagnosis of NSCLC;
  • Unresectable locally advanced, metastatic, or recurrent stage ⅢB-Ⅳ based on AJCC TNM staging 8th edition;
  • ECOG PS of 0-1;
  • Treatment naive;
  • Presence of at least one measurable lesion according to the RECIST v1.1;
  • Receiving targeted therapy or combination with chemotherapy;
  • Informed consent to participate in the study;
  • Driver gene-positive.

Exclusion Criteria:

  • Presence of other malignant tumors or malignant diseases within 3 years;
  • Concurrent acute or chronic psychiatric disorders;
  • Patients receiving sleep medication;
  • Prior participation in other clinical drug trials;
  • Symptomatic brain metastasis;
  • Inability to complete scale assessments.

Quoted from ClinicalTrials.gov, NCT06975384, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06975384, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06975384